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Abstract 
Chronic lymphocytic leukaemia (CLL) is characterised by heterogeneous clinical 
behaviour and there is a need for improved biomarkers. The current study evaluated 
the prognostic significance of serum free light chains (sFLC, kappa and lambda) and 
other serum markers (2M, serum thymidine kinase (sTK), soluble CD23 and LDH) 
together with established biomarkers in 289 patients enrolled into the LRF CLL4 trial. 
In a multivariable analysis of serum markers alone, higher 2M and Kappa light 
chains were statistically significant in predicting disease progression and higher 2M, 
and sTK in predicting mortality. In multivariable analysis for overall survival the 
following were independently significant: 2M levels, immunoglobulin gene (IGHV) 
mutational status (>98% homology), age, 17p13 deletions (>10%) and CD38 
expression. 2M is the only serum marker that retained clear independent value as a 
biomarker in the LRF CLL4 trial and remains powerfully prognostic requiring 
evaluation in any future method of risk stratifying patients.     
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Introduction 
Clinical heterogeneity within CLL provides a continuing impetus for the discovery and 
evaluation of novel biomarkers with prognostic and/or predictive value.  
Immunogenetic features, especially immunoglobulin gene (IGHV) mutational status, 
immunophenotypic markers such as CD38, CD49d and ZAP70, recurrent genomic 
copy number abnormalities and genomic mutations all have prognostic significance 
in CLL 1-4.  
A number of serum factors reflecting one or more CLL-related parameters such as 
tumour burden and cellular proliferation, activation and/or death have also been 
shown to correlate with a variety of outcome measures including time to first 
treatment, treatment response, progression free, and overall survival, and with other 
serum markers and biomarkers 5. Both serum Beta 2 microglobulin (2M)6 and 
serum thymidine kinase 1 (sTK) 7-11 are independent markers of progression free 
and overall survival  in trials of chemotherapy and chemo-immunotherapy. Soluble 
CD23 (sCD23) is associated with shorter PFS and OS in early stage patients 12-16 
and the doubling time of sCD23 appears more powerful than sCD2312. Serum lactate 
dehydrogenase (LDH) is an independent predictor of time to first treatment and is 
associated with shorter PFS, OS and with Richter's transformation 4,17.  
Despite the clinical validity of these markers and their relatively low cost, evidence 
for their clinical utility is less clear. This in part reflects methodological issues, the 
contribution of factors such as age and renal function to serum levels and whether 
prognostic significance is based on the evaluation of markers as a continuous 
variable or as a discontinuous variable with differing cut-offs among studies. 
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Free immunoglobulin light chains (FLC) are synthesised as a “by-product” of 
immunoglobulin synthesis. An abnormal serum FLC ratio (/) reflects clonal tumour 
production as the excess light chain type corresponds to the surface B cell receptor 
light chain type, whereas  elevated combined FLC concentrations ( plus  (cFLC)), 
in the presence of normal renal function and a normal FLC ratio, is due to polyclonal 
B-cell activation. Both an abnormal sFLC ratio and raised cFLC are markers of 
shorter time to first treatment and OS in CLL 18-20 and in a B cell tumour cFLC 
reflects both polyclonal B cell activation and clonal tumour production. However the 
prognostic significance of serum free light chains has not been evaluated in the 
context of a clinical trial. Previous studies have been limited to non-trial patients and 
therefore have a bias in terms of patient selection and variability in treatments 
delivered. To address this, we have determined the prognostic significance of serum 
2M, sTK, CD23, LDH and free light chains levels, both singly and in combination, in 
289 patients with available serum samples who participated in the LRF CLL 4 trial.  
 
Patient and study design 
The LRF CLL4 trial randomized 777 previously untreated patients with Binet stage 
progressive A, B or C disease between January 1999 and October 2004 to receive 
either chlorambucil, fludarabine or fludarabine and cyclophosphamide. Full details of 
the design, conduct and outcome of the LRF CLL4 trial have been published 21,22. 
Patients analysed in this study are a subset of those 541 randomised from October 
2001 onwards and represent all the patients in whom stored serum samples were 
available (n=289, 53%).  Last follow-up was in October 2010 for disease progression 
(6-9 years after randomisation) and September 2012 for survival (8-11 years after 
randomisation). In the previous analysis of prognostic factors in this study22, follow 
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up was until 31st Oct 2008 and the median follow up for survivors was 68 months so 
this current study had an additional 2 years follow up for PFS and 4 years for OS. All 
patients provided written informed consent. The trial was approved by the UK South 
Thames Multicentre Research Ethics Committee [MREC (1) 98/101] and followed 
UK Medical Research Council guidelines for good clinical practice. 
 
Laboratory markers 
The non-clinical prognostic factors were measured on blood samples taken at the 
time of trial entry. Details relating to the analysis of the following prognostic markers 
mutational analysis of immunoglobulin variable region genes (IGHV), fluorescence 
in-situ hybridisation (FISH) for p53, 11q deletion and trisomy 12, evaluation of CD38 
and ZAP-70 expression, have been previously described including the rationale for 
the cut offs used for Zap-70 (10%) and CD38% (7%)21,22. Our previous analysis of 
prognostic factors in the LRF CLL4 trial included two serum markers; serum lactate 
dehydrogenase and β-2M, both of which were measured by referring centres. In this 
study,evaluation of β-2M, CD23, serum thymidine kinase and serum free light chains 
were performed centrally. β-2 microglobulin (B2M) was measured by a latex 
enhanced immunoturbidimetric method on an Olympus AU640 clinical Chemistry 
analyzer (Olympus UK, Watford). The assay limit of detection was 0.064 mg/L and 
assay CVs were 3.8% at 0.8 mg/L, 3.5% at 1.5 mg/L and 3.1% at 2.2 mg/L. 
Serum CD23 (sCD23) was measured by a solid phase Enzyme Amplified Sensitivity 
Immunoassay (EASIA, Biosouce, Nivelles, Belgium) performed in accordance with 
the manufacturer’s instructions with the exception that, due to the anticipated higher 
values in CLL patients, a pre-dilution step was required. The assay limit of detection 
was 0.15U/ml and assay coefficient of variation (CV) was 9.4 at 2.2 U/ml and 4.2% 
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at 14.5 U/ml. Serum thymidine kinase activity was determined by a radioenzymatic 
technique (Prolifigen® TK-REA, Stillwater, MN) according to the manufacturer’s 
instructions. Serum TK activity (U/L) was derived from an appropriate standard 
curve. Intra-assay and inter-assay CVs were 3.67 and 5.27% respectively. 
Serum FLC concentrations were determined nephelometrically (FreeliteTM, The 
Binding Site, Birmingham, UK).  
 
Statistical Methods 
Serum marker variables are measured on a continuous scale. For clinical usage it 
might be useful to define a cut-off value for each, essentially dichotomising the scale. 
To assess the desirability of this approach, each serum marker was divided into 
quintiles comprising approximately 57 (289/5) patients in each quintile. Then within 
each quintile the percentage of cases that had progressed by 1 year and by 5 years 
and were dead at 5 years was determined (death by 1 year only occurred in 9% of 
patients) The chi-squared test for association was used to assess whether these 
percentages varied by quintile of serum marker, and this was then broken down into 
linear and non-linear components to further understand the nature of the association. 
Progression free survival (PFS) was calculated using time from randomization to 
progression or death (from any cause) and overall survival was calculated using time 
from randomization to death (from any cause). Survival times are shown graphically 
using Kaplan-Meier survival curves.   
The associations between survival (PFS and OS) and potential prognostic variables 
(demographic, genetic and serum markers) measured at baseline were modelled 
using Cox proportional hazards models. A 2-sided 5% significance level was used. 
Initially unadjusted analyses were carried out for each variable. Serum marker data 
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is sometimes divided by a constant (10 or 100) in order to improve readability of the 
odds ratios.  
 
A 2 phase approach was then used to derive parsimonious models (one for PFS and 
one for OS) that contained only statistically significant variables. Firstly all the 
significant variables within each of the 3 categories of demographic, established 
biomarkers and serum markers were modelled together within each category to 
determine the most important variables within each category. Forced entry of all 
variables and forward stepping methods were used, and from these analyses lists of 
significant variables in each category were derived. Variables that were not on these 
lists were then added in to the models singly to see if they were now significant. If 
they were, then they were kept in the model and the process repeated. In the second 
phase, all the statistically significant demographic, genetic and serum marker 
variables were brought together into the same model. Those that were not significant 
were dropped out using a backward stepping approach (though always leaving in 
treatment), and then not significant variables added in singly to see if they now 
contributed to the model. Treatment effect, a design variable for the trial from which 
the data were derived, is included in all these models. The analyses include as many 
cases as possible, but missing data on individual variables means that the sample 
size varies slightly depending on what variables are in the model. 
 
Of interest is whether serum markers might usefully replace more expensive genetic 
markers in helping to assess prognosis in clinical practice. Two models, one 
containing only serum markers and the other also containing genetic information 
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were compared using the Akaike Information Criterion. This allowed comparison of 2 
different, non-hierarchical models with the same outcome variable. It combines 
information on how well the model fits the data with information on the complexity of 
the model. Lower values imply a better model. Data were analysed using IBM SPSS 
Statistics Version 21. 
 
RESULTS 
Characteristics of the 289 patients from the LRF CLL4 trial analysed in this study are 
shown in Table 1. This cohort of patients is older, but otherwise comparable to the 
CLL4 trial overall (supplementary data Table 1s) in terms of gender, Binet stage and 
treatment allocation.  
Association between serum markers, divided into quintiles, PFS and OS 
The percentage of cases in each quintile that had progressed by 1 year and by 5 
years and had died by 5 years is shown in Table 2s. These data suggest that where 
serum markers are associated with risk of progression or survival, the risk tends to 
increase as serum marker values increase. The possible exceptions to this were 
Lambda and the Kappa/Lambda ratio, although there were no consistent patterns 
across the 3 outcome measures, and p-values were around the 5% level (in the 
context of multiple significance tests).   Given this set of results we felt it preferable 
to analyse the data as continuous variables rather than trying to dichotomise them.  
 
Univariable analysis of demographic factors, established biomarkers and 
serum factors. 
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Table 2 shows unadjusted hazard ratios summarising the associations of 
progression free survival and overall survival with demographic, established 
biomarker and serum marker variables.  
For demographic variables increasing age and male gender appear to be associated 
with greater risk of death, though not of disease progression. All the established 
biomarkers evaluated other than trisomy 12 (ie 11q deletion, no 13q deletion, 17p 
deletion, unmutated V genes, positive ZAP70, positive CD38 and TP53 mutation) 
were associated with increased risk of disease progression and death. 
For serum markers, increasing levels of β-2M, LDH, cFLC, kappa light chain, kappa/ 
lambda ratio (for progression only), CD23 and sTK (for overall mortality only) were 
associated with poor outcome. Hazard ratios adjusted for the effects of all other 
serum markers showed that only β-2M, and kappa light chains remained significant 
for PFS and β-2M, CD23 (in the opposite direction to the unadjusted analysis) and 
sTK  for OS (Table 3).  
  
Multivariable analysis for PFS and OS 
The final parsimonious models are shown in Table 4. Significant variables for 
disease progression included 11q deletion, 17p deletion, P53 mutation, IGHV 
mutation status. For mortality statistically significant variables included age, 13q 
deletion (associated with better survival), 17p deletion, IGHV mutation status, CD38 
positivity,  β-2M and CD23 (associated with better survival).   
 
Prognostic value of combining serum marker data.  
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As β-2M and sFLC are relatively inexpensive and readily available in the UK, we 
addressed the issue of whether the prognostic value of both factors might be 
comparable to that of established biomarkers. To this end two models were 
compared: one (model A) incorporating a selection of factors significant in our 
multivariable analysis and the other (model B) using kappa light chain and β-2M 
(Table 5)  The AIC statistic indicates that model A is superior to model B.  
 
DISCUSSION 
The primary aim of this study was to evaluate the prognostic significance of a 
number of different measures of serum free light chains: kappa/lambda ratio, kappa 
and lambda levels and combined kappa and lambda levels (cFLC). This was done 
using both univariable and multivariable analyses, which included age, a series of 
other serum factors (2M, sTK, sCD23 and LDH) and established biomarkers, in 
patients entered into the UK LRF CLL4 phase 3 chemotherapy trial. The rationale for 
the study was based on the observation that sFLC, measured within 3 - 9 months of 
diagnosis in predominantly early stage patients, predicts time to first treatment and 
overall survival but has not been evaluated in patients requiring treatment in a 
clinical trial setting.  We accept that previous studies of sFLC have predominantly 
examined treatment naïve patients at diagnosis including many patients with non-
progressive disease whilst the CLL4 study looks at prognostic variables for patients 
about to start therapy and hence a different population of patients. Serum markers 
offer practical advantages over other current biomarkers but their value needs to be 
proven in the context of large clinical trials against the established biomarkers. 
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The decision to analyse sFLC and all other serum markers as continuous variables 
in the study was based on the association of poorer outcomes with rising serum 
levels when values were divided into quintiles. This is consistent with the results of 
previous studies and although most utilised a single cut off, the prognostic 
nomogram developed by Wierda et al 23 includes β2M as a continuous variable and 
the recent scoring system described by Pflug et al 1 assigns one point for a β2M of 
1.7-3.5mg/L and two points for values above 3.5mg/L. When measures of serum free 
light chains were evaluated as continuous variables in univariable analysis, 
increasing levels of cFLC and kappa light chains were associated with a shorter PFS 
and OS.  When adjusted for the effects of all other serum markers, only kappa light 
chains remained significant for PFS, and this was lost in a multivariable analysis 
which included demographic and genetic factors. It is unclear why kappa should be 
more significant than cFLC in this study. cFLC has been shown to be prognostic both 
in other lymphoid tumours 24,25 but also in a general population without obvious 
haematological malignancies 26,27. The increased risk of death in a general 
population was not restricted to a particular cause of death but may reflect a chronic 
inflammatory state with polyclonal immunoglobulin production although this is 
unproven.    
In the previous study of prognostic factors in patients entered into the LRF CLL4 trial, 
a β2M level of greater than 4 mg/L, 11q and 17p deletion, unmutated IGHV genes 
and/or use of the IGHV3-21 gene, and treatment allocation were independent 
predictors of progression-free survival whilst 17p deletion, age, β2M level and IGHV 
mutational status and/or IGHV3-21 usage were independent predictors of overall 
survival22. Similar results were obtained in the current study of 289 patients, with the 
exception that β2M was no longer an independent predictor of PFS, nor 11q deletion 
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of OS, while CD38 positivity and the absence of 13q deletion independently 
predicted shorter OS. Possible factors to account for differences in the prognostic 
significance of β2M between the two studies include the smaller patient numbers and 
longer follow up in this study and the evaluation of 2M as a continuous variable 
rather than using the previous cut off of 4mg/dl. Patients with a creatinine clearance 
of less than 30 mL/min were excluded from this trial so high β2M levels are unlikely 
to reflect poor renal function.  
We found sTK, sCD23 and LDH to have prognostic significance in univariable 
analysis. sTK remained significant for OS when adjusted for other serum markers 
but in contrast to data from the German CLL trials, was not significant in 
multivariable analysis adjusting for genetic and demographic factors. This may 
reflect different methodologies as the German studies appear to use either a 
radioimmunoassay or quantitative immunoassay 1,5. 
 
The univariable analyses suggested an association between increasing CD23 and 
mortality, but this changed direction once B2M was taken into account in the 
multivariable analyses (ie an association between decreasing CD23 and mortality), If 
this finding is genuine it suggests that CD23 values need to be considered in the 
context of B2M values, and not in isolation. However CD23 was only weakly 
associated with OS and we did not feel that this would be plausible biologically or 
compatible with published literature. This result could reflect methodological issues, 
for example laboratory anomalies with non-linearity at high concentrations, or the 
need for more complex statistical models and would need replication in a different 
dataset.  
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As β2M and sFLC are widely available in the UK we were keen to explore a 
predictive model incorporating both β2M and kappa FLC.  However this was less 
powerful at predicting both PFS and OS compared to a model incorporating the 
factors significant in our multivariable analysis. Pflug et al 1 also noted that their 
prognostic model incorporating genomic abnormalities and IGHV mutational status 
as well as β2M and sTK, was more powerful than the Wierda model 23 which used 
age, gender, absolute lymphocyte count, Rai stage, number of nodal sites and β2M 
but no other biomarkers 
In summary, we found that β2M but not other serum markers had independent 
prognostic significance in the UK CLL4 trial and should be evaluated with genetic 
and immunophenotypic factors in future studies. Serum factors used alone produce 
an inferior prognostic model and in particular serum free light chains were not 
independently prognostic in this study. Whether any of these markers will have 
prognostic value in patients treated with novel non-chemotherapy regimens remains 
to be determined. Importantly our study does not refute the previous studies showing 
that sFLC predicts time to first treatment and overall survival in patients with no 
indication for immediate treatment.  
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Table 1: Characteristics of the 289 patients with available serum data in the 
CLL4 trial.  
 
Variable (N=289 unless otherwise stated) Descriptive statistics  
Gender % male 75% (216) 
Age at randomisation (years) Mean (SD) 65.0 (8.5)  
Min, Max  38, 84 
 
White blood cells x 109/L (N=287) Median (IQR) 96.1 (94.3)  Min, Max  4.6,  
541  
 
Haemoglobin g/l Mean (SD) 117 (23)  
Min, Max 40, 166  
 
Platelet count  x 109/L Median (IQR) 144.0 (87.5) 
 Min, Max 23, 684 
 
Enlarged spleen 57% (165) 
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Enlarged lymph nodes (a) Site 
                                     Neck 
                                    Axillae 
                                   Groin 
 
                                (b) Number of sites 
                                   0 
                                   1 
                                   2 
                                  3 
 
 70% (202),  
 71% (206),  
 52% (150) 
 
 
18% (53)  
14% (40)  
24% (70)  
44% (126) 
Binet staging (N=287)                           A 
                                             B 
                                             C 
 
24% (68)  
45% (130) 
 31% (89) 
Treatment Arm      Chlorambucil   
                       Fludarabine  
       Fludarabine and Cyclophosphamide 
49% (142)  
 26% (76)   
 25% (71) 
Clinical response 
Blank 
 
7% (21) 
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Complete response 
Nodular partial response 
None 
Progressive disease 
Partial response 
12% (35) 
20% (59) 
15% (44) 
7% (20) 
38% (110) 
OUTCOME VARIABLES  
Progression free survival (PFS) 
% Progressed at any time 
% Progressed by 1 year (Kaplan Meier) 
% Progressed by 5 years (Kaplan Meier) 
Median time  (95% CI) to progression 
(years) 
 
90% (260) 
31% (SE=3%) 90 events 
84% (SE=2%) 243 events 
1.9  (95% CI 1.6, 2.3) 
Overall survival (OS)% Died at any time 
% Died by 1 year (Kaplan Meier) 
% Died by 5 years (Kaplan Meier) 
% Died by 10 years (Kaplan Meier) 
Median time (95% CI) to death (years) 
 
69% (199) 
9% (SE=2%) 27 events 
46% (SE=3%) 132 events 
75% (SE=3%) 197 events 
5.8 years (95% CI 5.0, 6.6) 
GENETIC VARIABLES  
IGVH  (N=270) 
Mutated 
Unmutated 
 
36% (96) 
64% (174) 
TP 53 deletion (deletion 17p) (N=275) 8% (22) 
TP 53 mutation (N=240) 8% (18) 
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Both TP 53 deletion and TP53 mutation 6% (14) 
ATM deletion (deletion 11q) (N=274) 22% (59) 
ATM Mutation (N=64) 25% (16) 
Both ATM del and ATM mutation  10 patients (only 64 patients had data on 
mutation status) 
Deletion 13q (N=259) 57% (147) 
Trisomy 12 (N=259) 21% (55) 
ZAP70 (N=249) 
 
 
ZAP70 positive (over 10% cut off) 
Median (IQR)10.0 (21.5) 
 Min, Max  0, 93  
50% (125) 
CD38 (N=255) 
 
 
CD38 positive (over 7% cut off) 
Median (IQR) 20.0 (69.0)  Min, Max 0, 
100  
67% (170) 
NOTCH1 mutation (N=191) 8% (15) 
SF3B1 mutation (N=185) 15% (27) 
SERUM MARKERS  
B2M (mg/L) Median (IQR) 3.87 (2.09)  
 
Min, Max 1.28, 15.16  
 
LDH (U/L) (N=262) Median (IQR) 432.5 (222.7)  
Min, Max 4.0, 1953.0  
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Total Serum free light chain (mg/L) 
(N=286) 
Median (IQR) 45.2 (66.4)  
Min, Max 10.6, 801.1  
 
Kappa (mg/L) (N=287) Median (IQR) 14.8 (48.5)  
Min, Max  2.1,  530.8  
45% (130/287) had elevated Kappa 
(>19.4 mg/L)  
Lambda (mg/L) (N=286) Median (IQR) 13.0 (22.3)  
Min, Max 1.87,  791.7  
28% (79/286) had elevated Lambda (> 
26.3 mg/L) 
Kappa/Lambda ratio (N=286) Median (IQR) 1.65 (5.37) Min, Max  0.01, 
221.0  
 
CD23 (U/ml) (N=287) Median (IQR) 168 (159)  Min, Max  12,  
759  
 
STK level (U/L) (N=287) Median (IQR) 19.8 (41.1) 
Min, Max 1.6, 258.9  
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Table 2: Unadjusted hazard ratios for progression free and overall survival for 
selected demographic, established biomarkers and serum marker variables 
 Progression free survival Overall survival 
 Hazard ratio for 
disease 
progression 
(95% CI) 
p-
value 
Hazard ratio for 
mortality 
 (95% CI) 
p-value 
(a) Demographic     
Age (yrs) 1.007 (0.992, 1.022) 0.35 1.058 (1.039, 1.077) p<0.001 
Gender  
F 
M 
 
1.0 
1.20 (0.91, 1.59) 
0.20  
1.0 
1.52 (1.08. 2.15) 
p=0.02 
(a) (b) 
Established 
biomarkers 
    
Trisomy 12 
N 
Y 
 
1.0 
1.19 (0.87, 1.62) 
0.27  
1.0 
1.37 (0.97, 1.93) 
=0.08 
11q deletion 
N 
Y 
 
1.0 
1.67 (1.24, 2.25) 
0.001  
1.0 
1.45 (1.04. 2.01) 
=0.03 
13q deletion 
N 
Y 
 
1.0 
0.76 (0.58, 0.98) 
0.03  
1.0 
0.54 (0.40, 0.72) 
<0.001 
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17p deletion 
N 
Y 
 
1.0 
3.79 (2.42, 5.93) 
<0.001  
1.0 
4.17 (2.63, 6.62) 
<0.001 
IGVH 
Mutated 
Unmutated 
 
1.0 
2.22 (1.67, 2.93) 
<0.001  
1.0 
2.85 (2.03, 4.01) 
<0.001 
ZAP70 
Negative 
Positive 
 
1.0 
1.49 (1.14, 1.94) 
0.003  
1.0 
1.80 (1.32, 2.45) 
<0.001 
CD38 
Negative 
Positive 
 
1.0 
1.90 (1.43, 2.53) 
<0.001  
1.0 
2.65 (1.86, 3.79) 
<0.001 
TP53 mutation 
N 
Y 
 
 
1.0 
8.51 (4.95, 14.61) 
<0.001  
1.0 
3.35 (2.01, 5.56) 
<0.001 
SF3B1a 
N 
Y 
 
1.0 
1.28 (0.84, 1.93) 
0.25  
1.0 
1.73 (1.12, 2.68) 
0.01 
(c)Serum 
markers 
    
B2M (mg/L) 1.14 (1.08, 1.20) <0.001 1.24 (1.16, 1.31)  <0.001 
LDH/100 (U/L) 1.08 (1.03, 1.14) 0.001 1.13 (1.07, 1.20) <0.001 
Serum free light 
chain/10 
1.011 (1.001, 1.021) 0.037 1.013 (1.002, 1.024) 0.025 
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 aSF3B1 not subsequently used in multivariable analyses as 36% missing data 
  
(mg/L) 
Kappa/10 
(mg/L) 
1.030 (1.015, 1.046) <0.001 1.025 (1.009, 1.041) 0.003 
Lambda/10 
(mg/L) 
0.997 (0.980, 1.014) 0.72 1.001 (0.983, 1.019) 0.91 
Kappa/Lambda 1.006 (1.000, 1.012) 0.04 1.002 (0.995, 1.008) 0.59 
CD23/100 
(U/ml) 
1.099 (1.011, 1.195) 0.027 1.102 (1.005, 1.207) 0.039 
STK/10 
(U/L) 
1.023 (0.997, 1.050) 0.09 1.056 (1.026, 1.086) <0.001 
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Table 3:  Adjusted hazard ratios for progression free and overall survival for serum 
marker variables (only statistically significant variables shown) 
 Progression free survival Overall survival 
 Hazard ratio for 
disease 
progression 
 (95% CI) 
p-value Hazard ratio for 
mortality 
 (95% CI) 
p-value 
B2M (mg/L) 1.13 (1.07, 1.20) <0.001 1.33 (1.23, 1.44)  <0.001 
Kappa/10 (mg/L) 1.024 (1.008, 1.039) 0.003        -  
CD23/100 (U/ml)        -  0.839 (0.745, 0.944) 0.003 
STK/10 (U/L)       -  1.046 (1.015, 1.078) 0.003 
All hazard ratios adjusted for other serum markers and treatment group (a design 
variable in the CLL4  trial). . Variables that are not significant are not included in the 
model. 
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Table 4:  Adjusted hazard ratios for progression free and overall survival with 
demographic, established biomarkers and serum marker variables combined (only 
statistically significant variables shown) 
 Progression free survival 
n=226 
Overall survival n=224 
 Hazard ratio for 
disease 
progression 
(95% CI) 
p-value Hazard ratio for 
mortality 
(95% CI) 
p-value 
(a) Demographic     
Age (yrs)   1.063 (1.041, 1.086) <0.001 
(b) Established 
biomarkers 
    
11q deletion 
N 
Y 
 
1.0 
1.51 (1.08, 2.12) 
0.017   
13q deletion 
N 
Y 
   
1.0 
0.62 (0.44, 0.87) 
0.006 
17p deletion 
N 
Y 
 
1.0 
2.54 (1.26, 5.13) 
0.009  
1.0 
4.47 (2.65, 7.53) 
<0.001 
IGVH 
Mutated 
 
1.0 
<0.001  
1.0 
<0.001 
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Unmutated 1.92 (1.41, 2.61) 2.12 (1.42, 3.17) 
CD38 
Negative 
Positive 
   
1.0 
1.64 (1.08, 2.49) 
0.021 
TP53 mutation 
N 
Y 
 
1.0 
3.41 (1.56, 7.45) 
0.002   
(c) Serum 
markers 
    
B2M (mg/L)   1.33 (1.17, 1.51)  <0.001 
CD23/100 (U/ml)   0.752 (0.643, 0.880) <0.001 
Hazard ratios adjusted for all other variables in the model and treatment group (a 
design variable in the CLL4  trial). Variables that are not statistically significant are 
not included in the model. 
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Table 5: Comparison of 2 different clinical models for predicting progression free 
survival and overall survival (n=202). Model A:  Measures established  biomarkers 
and B2M to predict outcome. Model B: Measures B2M and serum free light chain 
variable 
Model Progression free survival Overall survival 
 Hazard ratio (95% 
CI) 
p-value Hazard ratio 
(95% CI) 
p-value 
Model A     
11q deletion 1.33 (0.93, 1.91) 0.12 1.15 (0.75, 1.75) 0.53 
13q deletion 0.86 (0.62, 1.18) 0.35 0.56 (0.38, 0.82) 0.003 
IGVH status 1.77 (1.22, 2.55) 0.002 1.58 (1.01, 2.47) 0.045 
CD38 positivity 1.17 (0.83, 1.65) 0.38 1.66 (1.09, 2.54) 0.020 
B2M (mg/L) 1.05 (0.96, 1.14) 0.33 1.12 (1.03, 1.23) 0.013 
     
AIC statistic1 1641.3  1220.8  
     
Model B     
B2M (mg/L) 1.09 (1.00, 1.18) 0.044 1.18 (1.08, 1.28) <0.001 
Kappa/10 (mg/L) 1.027 (1.008, 
1.047) 
0.006 1.013 (0.993, 
1.033) 
0.21 
     
AIC Statistic 1653.5  1247.2  
Same sample size of n=202 used for all analyses in the table. This excludes patients 
with TP53 mutation or deletion, and excludes patients from all analyses if they have 
missing data on any of 11q deletion, 13q deletion, v-gene, CD38, B2M or Kappa.  
 
 
27 
 
Supplementary 
Table 1S: Comparison of 289 patients with available serum data to 488 patients 
without available serum data in the CLL4 trial 
Variable  
No serum data 
n (%) 
Serum data 
n (%) 
p-value 
(heterogeneity) 
Gender 
 
F 
 
 
 
131 (27) 
 
73 (25) 0.69 
M  357 (73) 216 (75) 
 
Treatment 
allocation 
 
 
F+Cyclo 
 
 
 
 
 
125 (26) 
 
 
71 (25) 
 
          0.80 
Chlor  245 (50) 142 (49) 
Fluda  118 (24) 76 (26) 
Age group 
 
 
<60 
 
 
 
 
 
185 (38) 
 
 
70 (24) <0.001 
60-  159 (33) 127 (44) 
70+  144 (30) 92 (32) 
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Variable  
No serum data 
n (%) 
Serum data 
n (%) 
p-value 
(heterogeneity) 
Binet stage 
 
 
A 
 
 
 
 
 
122 (25) 
 
 
68 (24) 0.86 
B  220 (45) 130 (45) 
C  143 (30) 89 (31) 
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Table 2s: Preliminary serum marker analysis: Progression free survival and overall 
survival by quintiles of serum marker.   
 Quintiles Percent 
progressed 
at 1 year 
Percent 
progressed 
at 5 years 
Percent 
dead at 5 
years 
B2M (mg/L) 
 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 – 2.61 
2.62 – 3.50 
3.51 – 4.30 
4.31 – 5.36 
5.37 + 
 
 
17% 
25% 
26% 
37% 
51% 
 
0.001 
P<0.001 
0.71 
72% 
83% 
81% 
90% 
95% 
 
0.01 
0.001 
0.69 
21% 
32% 
44% 
58% 
75% 
 
<0.001 
<0.001 
0.91 
 
 
30 
LDH (U/L) 
 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 – 303 
304 – 388 
389 – 479 
480 – 571 
572+ 
 
 
21% 
31% 
25% 
37% 
46% 
 
0.04 
0.005 
0.56 
83% 
69% 
79% 
92% 
92% 
 
0.007 
0.01 
0.054 
40% 
38% 
31% 
56% 
63% 
 
0.004 
0.003 
0.09 
Total Serum free 
light chain 
(mg/L) 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 – 23.86 
23.87 – 37.70 
37.71 – 57.20 
57.21 – 111.03 
111.04+  
10% 
26% 
21% 
44% 
54% 
 
 
<0.001 
<0.001 
0.27 
69% 
84% 
88% 
89% 
89% 
 
 
0.01 
0.002 
0.30 
29% 
32% 
50% 
61% 
56% 
 
 
0.001 
<0.001 
0.33 
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Kappa (mg/L) 
 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 - 7.40 
7.41 – 12.38 
12.39 – 25.11 
25.12 – 64.84 
64.85+ 
 
 
21% 
26% 
22% 
32% 
54% 
 
<0.001 
<0.001 
0.11 
 
 
 
86% 
74% 
81% 
91% 
88% 
 
0.10 
0.19 
0.11 
34% 
39% 
36% 
59% 
61% 
 
0.003 
P<0.001 
0.36 
Lambda (mg/L) 
 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 – 5.40 
5.41 – 10.52 
10.53 – 17.89 
17.90 – 33.40 
33.41 + 
26% 
26% 
33% 
21% 
49% 
 
0.01 
0.03 
0.04 
74% 
84% 
82% 
86% 
93% 
 
0.10 
0.01 
0.74 
40% 
40% 
48% 
40% 
60% 
 
0.15 
0.06 
0.38 
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Kappa/Lambda 
ratio 
 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 – 0.260 
0.261 – 0.650 
0.651 – 2.700 
2.701 – 7.700 
7.701+ 
35% 
18% 
26% 
31% 
45% 
 
 
0.04 
0.12 
0.054 
90% 
85% 
72% 
84% 
88% 
 
 
0.08 
0.67 
0.04 
45% 
36% 
43% 
50% 
54% 
 
 
0.41 
0.15 
0.60 
CD23 
(U/ml) 
 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 – 88.92 
88.93 – 145.17 
145.18 – 200.84 
200.85 – 284.62 
284.63+ 
22% 
33% 
28% 
35% 
39% 
 
 
0.36 
0.08 
0.73 
72% 
82% 
86% 
93% 
86% 
 
 
0.046 
0.01 
0.31 
33% 
47% 
45% 
58% 
47% 
 
 
0.13 
0.07 
0.30 
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STK 
(U/L) 
 
 
 
 
Chi-squared test 
Overall p 
Trend p 
Non-linear p 
 
0 – 11.0060 
11.0061 – 15.2900 
15.2901 – 25.9560 
25.9561 – 60.5990 
60.5991+ 
 
19% 
28% 
28% 
44% 
39% 
 
 
0.04 
0.005 
0.52 
74% 
84% 
83% 
91% 
88% 
 
 
0.13 
0.03 
0.56 
30% 
46% 
43% 
49% 
60% 
 
 
0.03 
0.003 
0.67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
References 
1. Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for 
patients with chronic lymphocytic leukemia. Blood. Jul 3 2014;124(1):49-62. 
2. Pepper C, Majid A, Lin TT, et al. Defining the prognosis of early stage chronic lymphocytic 
leukaemia patients. British journal of haematology. Feb 2012;156(4):499-507. 
3. Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglobulin gene 
rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients 
independent of geographic origin and mutational status. Blood. Apr 1 2006;107(7):2889-
2894. 
4. Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to first treatment in 
patients with chronic lymphocytic leukemia. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. Nov 1 2011;29(31):4088-4095. 
5. Fink A, Pflug N, Busch R, et al. Serum Factors Predict Therapeutic Outcome In Patients with 
Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group 
(GCLLSG). ASH Annual Meeting Abstracts. November 19, 2010 2010;116(21):918-. 
6. Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is a better predictor of treatment-
free survival in patients with chronic lymphocytic leukaemia if adjusted according to 
glomerular filtration rate. British journal of haematology. Jun 2009;145(6):801-805. 
7. Matthews C, Catherwood MA, Morris TC, et al. Serum TK levels in CLL identify Binet stage A 
patients within biologically defined prognostic subgroups most likely to undergo disease 
progression. European journal of haematology. Oct 2006;77(4):309-317. 
8. Kallander CF, Simonsson B, Hagberg H, Gronowitz JS. Serum deoxythymidine kinase gives 
prognostic information in chronic lymphocytic leukemia. Cancer. Dec 1 1984;54(11):2450-
2455. 
 
 
35 
9. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a 
subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic 
leukemia. Blood. Mar 1 1999;93(5):1732-1737. 
10. Magnac C, Porcher R, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V 
mutational status in B-CLL. Leukemia. Jan 2003;17(1):133-137. 
11. Konoplev SN, Fritsche HA, O'Brien S, et al. High serum thymidine kinase 1 level predicts 
poorer survival in patients with chronic lymphocytic leukemia. American journal of clinical 
pathology. Sep 2010;134(3):472-477. 
12. Meuleman N, Stamatopoulos B, Dejeneffe M, El Housni H, Lagneaux L, Bron D. Doubling time 
of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A 
chronic lymphocytic leukemia patients. Leukemia. Oct 2008;22(10):1882-1890. 
13. Reinisch W, Willheim M, Hilgarth M, et al. Soluble CD23 reliably reflects disease activity in B-
cell chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. Oct 1994;12(10):2146-2152. 
14. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in 
chronic lymphocytic leukemia. Blood. Dec 1 1996;88(11):4259-4264. 
15. Molica S, Levato D, Dell'Olio M, et al. Cellular expression and serum circulating levels of 
CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. Haematologica. 
Sep-Oct 1996;81(5):428-433. 
16. Knauf WU, Ehlers B, Mohr B, et al. Prognostic impact of the serum levels of soluble CD23 in 
B-cell chronic lymphocytic leukemia. Blood. Jun 1 1997;89(11):4241-4242. 
17. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic 
leukaemia transformation to Richter syndrome. British journal of haematology. Jun 
2008;142(2):202-215. 
 
 
36 
18. Pratt G, Harding S, Holder R, et al. Abnormal serum free light chain ratios are associated with 
poor survival and may reflect biological subgroups in patients with chronic lymphocytic 
leukaemia. British journal of haematology. Jan 2009;144(2):217-222. 
19. Maurer MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light 
chains and clinical outcome in chronic lymphocytic leukemia. Blood. Sep 8 
2011;118(10):2821-2826. 
20. Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum-free light chain is 
a strong prognosticator in chronic lymphocytic leukemia. Blood. Dec 8 2011;118(24):6353-
6361. 
21. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide 
for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised 
controlled trial. Lancet. Jul 21 2007;370(9583):230-239. 
22. Oscier D, Wade R, Davis Z, et al. Prognostic factors identified three risk groups in the LRF 
CLL4 trial, independent of treatment allocation. Haematologica. Oct 2010;95(10):1705-1712. 
23. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in 
previously untreated patients with chronic lymphocytic leukemia. Blood. Jun 1 
2007;109(11):4679-4685. 
24. De Filippi R, Russo F, Iaccarino G, et al. Abnormally Elevated Levels of Serum Free-
Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and 
Predict Outcome of Patients with Early Stage Disease. ASH Annual Meeting Abstracts. 
November 20, 2009 2009;114(22):267-. 
25. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive 
markers of AIDS-related lymphoma. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. Feb 10 2010;28(5):773-779. 
 
 
37 
26. Dispenzieri A, Katzmann JA, Kyle RA, et al. Use of nonclonal serum immunoglobulin free light 
chains to predict overall survival in the general population. Mayo Clinic proceedings. Jun 
2012;87(6):517-523. 
27. Anandram S, Assi LK, Lovatt T, et al. Elevated, combined serum free light chain levels and 
increased mortality: a 5-year follow-up, UK study. Journal of clinical pathology. Nov 
2012;65(11):1036-1042. 
 
